Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.
This activity is intended for neurodegenerative disease specialists, general neurologists, primary care physicians, radiologists, neuroradiologists, emergency medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with early-stage AD neurobiology (mild cognitive impairment [MCI], early AD).
Upon completion of the educational activity, participants should be able to:
- Recognize key considerations that may impact a care team’s ability to successfully monitor for, identify, and/or treat ARIA and employ corresponding solutions to maximize interdisciplinary communication and patient outcomes
- Understand what and how to communicate to patients, families, and other healthcare professionals regarding the risk and presence of ARIA to ensure safe, comprehensive, and consistent care in patients prescribed amyloid targeting DMT
Check Out These Other ARIA Modules
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Disclosure of Financial Relationships
Medical Education Resources (MER) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners' and Managers' Disclosure
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.
Dr Galvin reported the following financial relationships:
- Consulting Fees: Alpha Cognition, Biogen, Cognivue, Eisai, Eli Lilly, Genentech/Roche, Otsuka
Dr Chiang has no financial relationships to disclose.
Dr Carpenter has no financial relationships to disclose.
Dr Vega has no financial relationships to disclose.
Disclosure of Unlabeled Use/Disclaimer
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
This continuing education activity is supported by an educational grant from Lilly.
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period June 26, 2023 through June 26, 2024, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
- 0.50 AAPA Category I CME
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance